SCN1A and Dravet syndrome: Here, we demonstrate that CAV-2–mediated expression of exogenous NaV1.1 activity, via a codon-modified SCN1A ORF, can significantly improve comorbidities in juvenile and adult DS mice, ameliorate the epileptic phenotypes, correct background ECoG activity, and improve cognitive functions.